drugset / Trial / NCT07040072
Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC
Phase 1
Recruiting
10 enrolled
Beijing Tongren Hospital
Keymed Biosciences Co.Ltd · collabSinocelltech Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, phase Ib study involving HNSCC patients who had received first-line treatment with either PD-1 combined with platinum-based drugs or PD-1 monotherapy. The aim of the study is to evaluate the safety and efficacy of Finotonlimab in combination with Stapokibart in the treatment of recurrent/metastatic HNSCC patients.
Timeline
- Start
- 2025-10-09
- Primary completion
- 2027-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM310 | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | Finotonlimab | Monoclonal antibody | 200 mg | Intravenous |